U.S. FDA Says Australian ChemGenex Needs Companion Diagnostic For Omapro

Australian-headquartered ChemGenex has agreed to meet with U.S. FDA in April to begin developing a validated assay test for determining which patients might benefit from its experimental chronic myeloid leukemia treatment Omapro.